Table 1 Population characteristics
Characteristics | All | Combined with previously used drugs | ||
|---|---|---|---|---|
Primary resistance | Secondary resistance | None | ||
All patients | 120 | 19 (16%) | 20 (17%) | 81 (67%) |
Mean age/years (range) | 52.6 (24–84) | 53.4 (31–76) | 54.9 (25–75) | 51.9 (24–84) |
Nuclear grade, No. (%) | ||||
 1 | 4 (3%) | 1 (5%) | 0 (0%) | 3 (4%) |
 2 | 92 (77%) | 13 (68%) | 15 (75%) | 64 (79%) |
 3 | 24 (20%) | 5 (26%) | 5 (25%) | 14 (17%) |
Pathological type, No. (%) | ||||
 Infiltrating ductal carcinoma | 112 (93%) | 19 (100%) | 16 (80%) | 77 (95%) |
 Infiltrating lobular carcinoma | 8 (7%) | 0 (0%) | 4 (20%) | 4 (5%) |
HER2 status, No. (%) | ||||
 Negative | 104 (87%) | 18 (95%) | 18 (90%) | 68 (84%) |
 Positive | 16 (13%) | 1 (5%) | 2 (10%) | 13 (16%) |
Number of metastatic sites, No. (%) | ||||
 0–2 | 66 (55%) | 9 (47%) | 10 (50%) | 47 (58%) |
 ≥3 | 54 (45%) | 10 (53%) | 10 (50%) | 34 (42%) |
Number of chemotherapy lines, No. (%) | ||||
 0–2 | 68 (57%) | 11 (58%) | 8 (40%) | 49 (60%) |
 ≥3 | 52 (43%) | 8 (42%) | 12 (60%) | 32 (40%) |
Number of endocrine therapy lines, No. (%) | ||||
 0–1 | 22 (18%) | 1 (5%) | 2 (10%) | 19 (23%) |
 ≥2 | 98 (82%) | 18 (95%) | 18 (90%) | 62 (77%) |
The drug combined with, No. (%) | ||||
 SERM | 19 (16%) | 5 (26%) | 5 (25%) | 9 (11%) |
 SERD | 18 (15%) | 2 (11%) | 2 (10%) | 14 (17%) |
 NSAI | 24 (20%) | 4 (21%) | 8 (40%) | 12 (15%) |
 EXE | 59 (49%) | 8 (42%) | 5 (25%) | 46 (57%) |
Visceral metastases, No. (%) | ||||
 Yes | 54 (45%) | 5 (26%) | 8 (40%) | 41 (51%) |
 No | 66 (55%) | 14 (74%) | 12 (60%) | 40 (49%) |